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Background: Accurate predictors of survival for patients with advanced gastric cancer treated with neoadjuvant
chemotherapy are currently lacking. In this study, we aimed to evaluate the prognostic significance of the
neutrophil-lymphocyte ratio (NLR) in patients with stage III-IV gastric cancer who received neoadjuvant
chemotherapy.
Methods: We enrolled 46 patients in this study. The NLR was divided into two groups: high (>2.5) and low (≤2.5).
Univariate analysis on progression-free survival (PFS) and overall survival(OS) was performed using the Kaplan-Meier
and log-rank tests, and multivariate analysis was conducted using the Cox proportional hazards regression model.
We analyzed whether chemotherapy normalized high NLR or not, and evaluated the prognostic significance of
normalization on survival.
Results: The univariate analysis showed that PFS and OS were both worse for patients with high NLR than for
those with low NLR before chemotherapy (median PFS 16 and 49 months, respectively, P = 0.012; median OS 21
and 52 months, P = 0.113). PFS and OS were also worse for patients with high NLR than for those with low NLR
before surgery (median PFS 12 and 35 months, P = 0.019; median OS 21 and 52 months, P = 0.082). Multivariate
analysis showed that both NLR before chemotherapy and surgery were independent prognostic factors of PFS.
Neoadjuvant chemotherapy normalized high NLR in 11 of 24 patients, and these 11 patients had better median PFS
and OS than the 13 patients who had high NLR both before chemotherapy and before surgery (PFS: 35.0 and 10.0
months, P = 0.003; OS: 60 and 16 months, P = 0.042).
Conclusions: NLR may serve as a potential biomarker for survival prognosis in patients with stage III-IV gastric
cancer receiving neoadjuvant chemotherapy.
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Gastric cancer is the one of the most common cancer
types and is the leading cause of cancer-related death
worldwide. Annually, nearly 1 million new cases are diag-
nosed, and more than 700,000 deaths are estimated to
occur from this disease [1]. Increased use of adjuvant and
neoadjuvant treatment regimens such as radiotherapy and* Correspondence: yujr0909@zju.edu.cn
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reproduction in any medium, provided the orneoadjuvant chemotherapy has greatly improved both
progression-free survival (PFS) and overall survival (OS)
[2], and it has been reported that it is possible to deliver
neoadjuvant chemotherapy without increasing surgical
morbidity and mortality compared with surgery alone [3].
However, it is necessary to find accurate predictors of out-
comes for neoadjuvant chemotherapy in order to identify
those patients who are more likely to benefit from
neoadjuvant chemotherapy. Although a few serum bio-
markers have been found to be associated with poor prog-
nosis in patients with gastric cancer [4,5], their use is
often time-consuming and expensive. Recently, novelThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Survival of patients treated with different neoadjuvant chemotherapy regimens. (A) Progression-free survival and (B) overall survival.
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identified [6-8]. However, these largely depend on speci-
mens obtained after resection of the primary tumor, and
this limits their use in clinical practice prior to surgery.
A systemic inflammatory response has been reported to
be associated with the progression of cancer [9,10].
Coussens et al. [9] reported that the ability of a tumor to
invade and metastasize was dependent on the intrinsic
characteristics of the tumor cells, as well as the tumor
microenvironment. Peripheral blood tests at the time of
diagnosis and treatment can reflect inflammatory condi-
tions within the tumor. Evaluation of peripheral blood pa-
rameters including C-reactive protein (CRP), leukocytes,neutrophil, lymphocyte, monocyte, and platelet counts, as
well as the modified Glasgow Prognostic Score (mGPS),
neutrophil to lymphocyte ratio (NLR), and platelet to
lymphocyte ratio (PLR), have been proposed as prognostic
factors for patients with various types of malignancies. An
elevated serum CRP level was associated with poor sur-
vival in patients with gastro-esophageal cancer [11], ovar-
ian cancer [12], and renal cancer [13], while elevated
neutrophil, monocyte, and leukocyte counts have been
reported to be associated with poor survival in patients
with metastatic melanoma [14,15]. A high pre-operative
NLR has been identified as a useful and convenient pre-
dictor of survival in patients with gastric cancer [16-20],
Table 1 Demographic and clinicopathological











Cycles of chemotherapy, median (range) 3 (1–5)
Primary tumor site
Upper 1/3 12 (26.1%)
Middle 1/3 12 (26.1%)































Table 1 Demographic and clinicopathological




















CR, complete response, PD, progressive disease; PR, partial response; SD, stable
disease; Tis, tumor in situ; TNM, tumor, node metastasis;
aClinical response: Yes means CR and PR; No means SD and PD.
bClinical benefit: Yes means CR and PR and SD; No means PD.
cWell and moderately differentiated adenocarcinoma.
dPoorly differentiated adenocarcinoma, ring cell carcinoma.
eAmerican Joint of Committee On Cancer, sixth edition.
fClassification after neoadjuvant chemotherapy.
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lung cancer [23]. Recently, Dutta S et al. [24] reported that
the mGPS was independently associated with cancer-
specific survival in patients undergoing potentially cura-
tive resection of gastric cancer, and an increase in the
mGPS was associated with higher NLR and poorer sur-
vival. However, the usefulness of NLR in patients with ad-
vanced malignancies receiving neoadjuvant chemotherapy
has been reported only rarely [25-27]. Kunisaki C et al.
[25] found that there were significant correlations between
the GPS and NLR in patients with advanced gastric cancer
receiving biweekly docetaxel and S-1 combination chemo-
therapy, and patients with low GPS group may obtain
favorable outcomes with chemotherapy. An analysis
conducted by Kishi et al. [26] showed that a high NLR
independently predicted poor survival in patients with
colorectal liver metastases treated with chemotherapy
followed by resection or chemotherapy alone, and that
normalization of the high NLR by neoadjuvant chemo-
therapy indicated improved survival.
To our knowledge, the prognostic significance of pre-
treatment NLR including pre-chemotherapy and pre-
Table 2 Results of the univariate and multivariate analyses of progression-free survival in 46 patients with stage III-IV





HR (95% CI) P value
Radicality
R0 37 0.163 (0.063 to 0.421) <0.001
R1
R2 9 <0.001 1
Differentiation
Differentiatedc 15







>2.5 24 0.012 2.329 (1.069 to 5.073) 0.033






>2.5 20 0.019 2.347 (1.128 to 4.881) 0.022
HR, hazard ratio; NLR, Neutrophil to lymphocyte ratio.
aPerformed using the Kaplan-Meier analysis model and log-rank test; values of P<0.10 in the univariate analysis were entered into a multivariate analysis.
bPerformed using Cox proportional hazards models with the backward likelihood method.
cDifferentiated include: well and moderately differentiated adenocarcinoma.
dPoorly differentiated include: poorly differentiated adenocarcinoma, ring cell carcinoma.
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tric cancer treated with neoadjuvant chemotherapy. The
aim of the present study was to evaluate the prognostic
significance of pre-chemotherapy and pre-operative NLR
in peripheral blood samples from patients with stage III-
IV gastric cancer receiving neoadjuvant chemotherapy. In
addition, we determined whether neoadjuvant chemother-
apy normalized high pre-chemotherapy NLR, and assessed
the effect of NLR normalization on survival.
Methods
Ethics approval
The study was approved by the ethics committee of the
First Affiliated Hospital, Medical College, Zhejiang Uni-
versity, and prior to the research, informed consent was
obtained from all patients.
Patients
In total, 58 patients diagnosed with advanced gastric can-
cer and treated with neoadjuvant chemotherapy in theDepartment of Gastrointestinal Surgery, First Affiliated
Hospital, Medical College, Zhejiang University were en-
rolled in this study between July 2004 and May 2009. All
patients fulfilled the following criteria: locally advanced,
T3-T4 carcinoma staged according to the sixth edition of
the American Joint Committee on Cancer (AJCC) guide-
lines, without distant metastases; no previous chemother-
apy or radiotherapy; and adequate hematological, liver and
renal function. Of the 58 patients, 3 had not undergone
gastrectomy (2 had undergone opening and closure, and
one had undergone palliative gastrojejunostomy), 3 had
been diagnosed with other malignancies simultaneously
(2 with rectal cancer and 1 with lung cancer), and another
2 patients showed evidence of infection at the time of
blood sampling, thus ultimately, 50 patients were eligible
for inclusion in this study.
Patients were treated with one of two neoadjuvant
chemotherapy regimens: oxaliplatin plus capecitabine
(XELOX) or oxaliplatin plus 5-fluorouracil (5-FU) plus
leucovorin (FOLFOX). As there were no significant
Table 3 Results of the univariate and multivariate analyses of overall survival in 46 patients with stage III-IV gastric





HR (95% CI) P value
Radicality
R0 37 0.127 (0.050 to 0.320) <0.001
R1
R2 9 <0.001 1
Differentiation
Differentiatedc 15








HR, hazard ratio; NLR, Neutrophil to lymphocyte ratio.
aPerformed using the Kaplan-Meier analysis model and log-rank test; values of P <0.10 in the univariate analysis were entered into a multivariate analysis.
bPerformed using Cox proportional hazards models with the backward likelihood method.
cWell and moderately differentiated adenocarcinoma.
dPoorly adenocarcinoma, ring cell carcinoma.
Jin et al. World Journal of Surgical Oncology 2013, 11:112 Page 5 of 10
http://www.wjso.com/content/11/1/112differences between the two chemotherapy regimen
groups regarding either median PFS (26 versus 30
months; P = 0.991; Figure 1A) or median OS (36 versus
34 months; P = 0.845; Figure 1B), data from both groups
were combined in this study. For 4 of the 50 eligible pa-
tients, data on blood parameters before surgery were not
available (missing data <10%). Thus, data from 46 pa-
tients were analyzed in the present study.
Blood parameters
Venous blood samples were taken at the time of diagnosis
before neoadjuvant chemotherapy, and 4 weeks or more
after the last dose of chemotherapy and within 1 week be-
fore surgery (when hematotoxicity had been minimized).
NLR was defined as neutrophil count divided by lympho-
cyte count. The cut-off values for white blood cells
(>6,000/mm3 and ≤6,000/mm3), neutrophils (>4,000/mm3
and ≤4,000/mm3), lymphocytes (>1,500/mm3 and ≤1,500/
mm3), monocytes (>500/mm3 and ≤500/mm3) and NLR
(>2.5 and ≤2.5) were defined using the median values and
data from previous studies [17].
Statistical analysis
Response rates were evaluated according to the Response
Evaluation Criteria In Solid Tumors (RECIST) guidelines
[28]. Clinical response was defined as either complete re-
sponse (CR) or partial response (PR), and non-response as
either stable disease (SD) or progressive disease (PD).Clinical benefit was defined as CR, PR or SD, and no
benefit was defined as PD. The follow-up period com-
menced at the start of neoadjuvant chemotherapy with a
censor date of April 2012. PFS was calculated from the
date of initiation of neoadjuvant chemotherapy until ob-
jective tumor progression, death, or last contact. OS was
calculated from the date of initiation of neoadjuvant
chemotherapy until death or last contact. Potential prog-
nostic factors were age, gender, tumor site, clinical re-
sponse, clinical benefit, type of surgery, radicality of
surgery, tumor differentiation, and peripheral blood pa-
rameters; these were entered into a univariate analysis
using the Kaplan–Meier analysis model and differences
between groups were compared by log-rank test. Prognos-
tic factors with significance values of P<0.10 in the univar-
iate analysis were entered into a multivariate analysis,
which was performed using Cox proportional hazards
model with the backward likelihood method to test for in-
dependent prognostic variables.
All statistical analyses were performing using SPSS
software (version 16.0; SPSS Inc., Chicago, IL, USA), and




Table 1 shows the characteristics of the 46 patients: 36
were male and 10 were female, with a median age of 60
Figure 2 Kaplan-Meier survival curves according to neutrophil-lymphocyte ratio (NLR) before neoadjuvant chemotherapy.
(A) Progression-free survival and (B) overall survival. P values were determined using the log-rank test.
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a XELOX neoadjuvant chemotherapy regimen and 14 pa-
tients received a FOLFOX regimen. The median number
of chemotherapy cycles was three (range one to five). All
46 patients underwent gastrectomy; 28 (60.9%) under-
went total gastrectomy and 18 (39.1%), subtotal gastrec-
tomy, with 1 patient receiving combined resection of the
transverse colon. Clinical and pathological TNM (tumor,
node, metastasis) classification based on the AJCC sta-
ging were as follows: clinical TNM classification showed
that 40 patients had stage III disease and 6 had stage IV
disease, while pathological TNM classification based on
specimens obtained after resection of the primary tumorshowed that 23 patients had stage III disease and 11 had
stage IV disease.Blood parameters
The median pre-chemotherapy white blood cell, neutro-
phil, lymphocyte, and monocyte counts were 6,400,
3,900, 1,550, and 500 per mm3, respectively. The median
pre-chemotherapy NLR was 2.74 (range 0.91 to 7.00),
and the median pre-operative NLR was 2.35 (range 0.70
to 6.00). An NLR value of 2.5 was used as the cut-off
value to classify patients into high (>2.5) or low (≤2.5)
NLR groups.
Figure 3 Kaplan-Meier survival curves according to neutrophil-lymphocyte ratio (NLR) before surgery. (A) Progression-free survival and
(B) overall survival. P values were determined using the log-rank test.
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For the 46 patients, the median PFS was 26.0 months, and
the median OS was 34.0 months. In univariate analysis,
variables predicting improved PFS were R0 resection, well
and moderately differentiated tumor, pre-chemotherapy
neutrophil count of 4,000/mm3 or less, pre-chemotherapy
NLR 2.5 or less, pre-operative neutrophil count 4,000/
mm3 or less, and pre-operative NLR 2.5 or less (Table 2).
The following variables were associated with improved
OS: R0 resection, well and moderately differentiated
tumor, pre-operative neutrophil count 4,000/mm3 or less
and pre-operative NLR 2.5 or less (Table 3). The pre-chemotherapy parameters appeared to have no prognos-
tic values on OS (pre-chemotherapy neutrophil count
P = 0.154; pre-chemotherapy NLR P = 0.113) (data not
shown). Meanwhile, we found that pre-chemotherapy and
pre-operative lymphocyte count had no prognostic sig-
nificance using the cut-off value of 1500/mm3 on PFS
(pre-chemotherapy lymphocytes P = 0.803; pre-operative
lymphocytes; P = 0.615) or OS (pre-chemotherapy lym-
phocytes P = 0.744; pre-operative lymphocytes P = 0.647)
in univariate analysis (data not shown). Median PFS and
median OS were worse for patients with high NLR values
than for those with low NLR values before chemotherapy
Table 4 Survival of patients according to neutrophil-lymphocyte ratio (NLR) before both neoadjuvant chemotherapy
and surgery
NLR changed by chemotherapya Number PFS OS
Median survival, months P value Median survival, months P value
NLR >2.5 → NLR >2.5 13 10 16
NLR ≤2.5 → NLR ≤2.5 15 49 <0.001 42 0.015
NLR >2.5 → NLR ≤2.5 11 35 60
NLR ≤2.5 → NLR ≤2.5 15 49 0.648 42 0.869
NLR >2.5 → NLR ≤2.5 11 35 60
NLR >2.5 → NLR >2.5 13 10 0.003 16 0.042
NLR, Neutrophil to lymphocyte ratio.
aChange between pre-chemotherapy and pre-operative NLR.
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P = 0.012; median OS 21 months and 52 months,
P = 0.113) (Figure 2A,B). Worse median PFS and median
OS was also seen in patients with high NLR values than
those with low NLR values after neoadjuvant chemother-
apy but before surgery (median PFS 12 months and 35
months, respectively; P = 0.019; median OS 21 months
versus 52 months; P = 0.082) (Figure 3A,B). Multivari-
ate analysis identified high pre-chemotherapy NLR
(P = 0.033, hazard ratio (HR) = 2.329, 95% CI 1.069 to
5.073) and high pre-operative NLR (P = 0.022, HR =
2.347, 95% CI 1.128 to 4.881) as independent factors asso-
ciated with worse PFS (Table 2), but both lost independent
prognostic significance for OS upon multivariate analysis
(Table 3).
Normalization of pre-chemotherapy NLR and correlation
with PFS and OS
Of the 46 patients, 24 had NLR values above 2.5 before
chemotherapy, and 11 of these had NLR values of 2.5 or
less before surgery. Of the 22 patients with NLR values of
2.5 or less before chemotherapy, 7 had NLR values above
2.5 before surgery. The 11 patients with NLR nor-
malization had better median PFS (35.0 versus 10.0
months; P = 0.003) and better median OS (60 versus 16
months; P = 0.042) than the 13 patients with NLR values
above 2.5 before both chemotherapy and surgery, and
similar median PFS (35 versus 49 months; P = 0.648 ) and
median OS (60 versus 42 months; P = 0.869) as the 15 pa-
tients with NLR of 2.5 or less before both chemotherapy
and surgery (Table 4).
Discussion
Gastric cancer is one of the most common types of ma-
lignancies worldwide, leading to hundreds of thousands
of deaths annually. Multimodal therapy, including radio-
therapy, adjuvant chemotherapy, and targeted therapy,
has greatly improved the survival of patients with ad-
vanced gastric cancer. Neoadjuvant chemotherapy is
currently in the limelight, with verification of its efficacyand safety now under way [29]. However, in order to se-
lect the optimal treatment regimen for individuals, ac-
curate predictors that identify those patients who are
more likely to benefit from neoadjuvant chemotherapy
are needed.
Peripheral blood samples can be easily obtained for pre-
treatment prediction. Several studies have established sys-
temic inflammation-based prognostic scores before surgery
[30-33]. A study conducted by Proctor et al. [31], which
enrolled 8,759 patients diagnosed with a variety of cancers
showed that the systemic inflammation-based scores, in-
cluding the mGPS, NLR, PLR, Prognostic Index, and
Prognostic Nutritional Index, have prognostic value. In
particular, NLR has been reported to be a useful prognostic
factor in gastric cancer [16-20]. Hirashima et al. [16] first
suggested that high NLR was associated with poor OS in
patients with early gastric cancer, and Jung et al. [20]
showed that raised pre-operative NLR predicted poor
disease-free survival and OS following resection for late-
stage gastric cancer. However, to our knowledge, the prog-
nostic significance of NLR in patients with advanced
gastric cancer receiving neoadjuvant chemotherapy has
rarely been studied. We analyzed the relationship between
pre-chemotherapy and pre-operative NLR scores and sur-
vival in patients with stage III-IV gastric cancer. In
addition, we evaluated whether neoadjuvant chemotherapy
normalized high NLR, and evaluated the effect of such
NLR normalization on survival.
Our results showed that high pre-chemotherapy NLR
and high pre-operative NLR independently predicted
worse PFS in patients with stage III-IV gastric cancer re-
ceiving neoadjuvant chemotherapy, and that high NLR
pre-operative was associated with poor OS in univariate
analysis. Although high pre-operative NLR lost its inde-
pendent prognostic significance for OS in multivariate
analysis, it still provided important information on NLR
for clinical practice. A study by Kishi et al. [26] suggested
that high NLR was a useful predictor of worse survival in
patients with colorectal liver metastases treated with
chemotherapy alone or with chemotherapy followed by
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study. Kishi et al. also demonstrated that normalization of
high NLR by chemotherapy indicated improved survival.
In our study, we found that high NLR values were normal-
ized after neoadjuvant chemotherapy in 11 patients, and
that normalization of high NLR indicated improved PFS
and OS, with patients in whom it occurred having similar
survival to those with low NLR before both chemotherapy
and surgery.
The association between elevated NLR and poor sur-
vival in patients with various types of cancers has not been
clearly defined until now. It is possible that pre-treatment
neutrophil and lymphocyte numbers indicate the level of
inflammation within the tumor, and thus predict progno-
sis. Indeed, there are several possible explanations for this.
Cytokines generated by neutrophils, such as vascular
endothelial growth factor, interleukin-18 and matrix
metalloproteinases [34-36], may establish a microenviron-
ment that promotes angiogenesis, and thus promotes
tumor growth and metastasis. In addition, the increased
number of neutrophils around the tumor may suppress
the anti-tumor immune responses of natural killer cells
and activated T cells [37,38]. At the same time, a reduced
number of lymphocytes may weaken the lymphocyte-
mediated anti-tumor cellular immune response. Hence, it
is likely that the combined effects of neutrophilia and
lymphocytopenia lead to a high NLR and thus promote
angiogenesis and inhibit anti-tumor reactivity, ultimately
leading to tumor growth and progression.
To our knowledge, this is the first study of the associa-
tions of pre-chemotherapy and pre-surgery NLR values
with PFS and OS in patients with advanced gastric cancer
receiving neoadjuvant chemotherapy. Notably, we evalu-
ated the prognostic significance of NLR normalization due
to neoadjuvant chemotherapy for survival. Thus, the
present study may provide important information for clin-
ical practice. However, as our study was retrospective and
the number of patients was small, larger numbers of
patients with advanced gastric cancer treated with neo-
adjuvant chemotherapy should be enrolled in a well-
designed prospective study. Although the peripheral blood
samples were obtained 4 weeks after the last dose of
chemotherapy, when hematotoxicity had been minimized,
its influence could not be excluded completely. Moreover,
whether the cut-off value of 2.5 for NLR is correct re-
quires further investigation.
Conclusions
NLR could be a convenient, easily measured prognostic
indicator for patients with stage III-IV gastric cancer
treated with neoadjuvant chemotherapy. Patients with
high pre-treatment NLR values need multimodal ther-
apy, and normalization of high NLR by neoadjuvant
chemotherapy indicates a good chemotherapy responserate and improved survival. Pre-treatment NLR may help
clinicians to identify those patients who will benefit from
neoadjuvant chemotherapy, and normalization of NLR
by chemotherapy may represent a good prognostic indi-
cator. However, further studies involving greater num-
bers of patients with gastric cancer are required.
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